Brokerages expect VBI Vaccines Inc (NASDAQ:VBIV) to post $860,000.00 in sales for the current quarter, Zacks reports. Two analysts have issued estimates for VBI Vaccines’ earnings, with the lowest sales estimate coming in at $500,000.00 and the highest estimate coming in at $1.21 million. VBI Vaccines posted sales of $640,000.00 in the same quarter last year, which suggests a positive year over year growth rate of 34.4%. The business is scheduled to issue its next quarterly earnings report on Friday, August 14th.
According to Zacks, analysts expect that VBI Vaccines will report full year sales of $3.31 million for the current year, with estimates ranging from $2.00 million to $4.62 million. For the next fiscal year, analysts forecast that the company will post sales of $6.18 million, with estimates ranging from $4.10 million to $8.25 million. Zacks’ sales averages are an average based on a survey of analysts that cover VBI Vaccines.
VBI Vaccines (NASDAQ:VBIV) last released its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. VBI Vaccines had a negative net margin of 2,133.79% and a negative return on equity of 57.79%. The company had revenue of $0.42 million during the quarter, compared to analysts’ expectations of $0.83 million.
VBIV traded up $0.14 on Monday, reaching $3.13. The stock had a trading volume of 11,861,720 shares, compared to its average volume of 8,141,211. VBI Vaccines has a 12-month low of $0.47 and a 12-month high of $3.50. The company has a current ratio of 1.30, a quick ratio of 1.28 and a debt-to-equity ratio of 0.01. The business’s 50-day moving average price is $2.20 and its two-hundred day moving average price is $1.47. The company has a market cap of $689.64 million, a P/E ratio of -8.94 and a beta of 1.69.
In other VBI Vaccines news, major shareholder Life Sciences Maste Perceptive purchased 9,090,909 shares of the stock in a transaction that occurred on Friday, April 24th. The shares were purchased at an average cost of $1.21 per share, for a total transaction of $10,999,999.89. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 10.00% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. State Street Corp boosted its position in VBI Vaccines by 15.1% during the first quarter. State Street Corp now owns 2,362,367 shares of the biopharmaceutical company’s stock worth $2,244,000 after acquiring an additional 310,001 shares during the last quarter. Royal Bank of Canada boosted its position in VBI Vaccines by 832.1% during the first quarter. Royal Bank of Canada now owns 35,437 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 31,635 shares during the last quarter. Integrated Wealth Concepts LLC acquired a new position in VBI Vaccines during the first quarter worth about $35,000. Wells Fargo & Company MN boosted its position in VBI Vaccines by 375.6% during the first quarter. Wells Fargo & Company MN now owns 106,800 shares of the biopharmaceutical company’s stock worth $102,000 after acquiring an additional 84,346 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its position in VBI Vaccines by 70.7% during the first quarter. Alliancebernstein L.P. now owns 153,800 shares of the biopharmaceutical company’s stock worth $146,000 after acquiring an additional 63,700 shares during the last quarter. Hedge funds and other institutional investors own 33.88% of the company’s stock.
About VBI Vaccines
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.
Recommended Story: Options Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.